Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3136 - Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC)

Date

10 Sep 2017

Session

Poster display session

Presenters

Vincenza Conteduca

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

V. Conteduca1, S. Salvi2, P. Caroli3, E. Scarpi4, G. Schepisi1, C. Lolli1, D. Wetterskog5, S.L. Burgio1, C. Menna1, V. Casadio2, F. Matteucci3, G. Paganelli3, G. Attard6, U. De Giorgi1

Author affiliations

  • 1 Department Of Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 2 Biosciences Laboratory, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 3 Nuclear Medicine Operative Unit, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 4 Unit Of Biostatistic And Clinical Trial, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 5 Treatment Resistance, Division Of Molecular Pathology, The Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 6 Treatment Resistance, Division Of Molecular Pathology, The Institute of Cancer Research (Sutton Site), SM2 5NG - Sutton/GB
More

Resources

Abstract 3136

Background

Biomarkers for treatment personalization in mCRPC could improve patient outcomes. Multiple tests on blood have reported associations with worse outcome, including serum lactate dehydrogenase (LDH), chromogranin A (CgA), neutrophil-lymphocyte ratio (NLR) and more recently AR copy number (CN) in plasma DNA (Conteduca, Ann Oncol 2017). Biological data suggest an association between choline uptake and androgen receptor (AR) expression. We here aimed to integrate 18F-fluorocholine (FCH) uptake on PET/CT with plasma AR CN and other routinely obtained circulating biomarkers and evaluate associations with outcome.

Methods

We determined plasma AR DNA by digital PCR and Taqman from 105 CRPC samples collected before abiraterone (n = 65) or enzalutamide (n = 40). Pre-treatment serum LDH, CgA, NLR were also measured. FCH-PET/CT scan was performed at baseline and SUVmax, total lesion activity (TLA) and metabolic tumor volume (MTV) were calculated. Patients (pts) were dichotomized in high and low according to receiver-operating characteristic (ROC) curves. Main endpoints were the correlation of FCH-PET/CT parameters with circulating biomarkers and their impact on progression-free/overall survival (PFS/OS).

Results

Plasma AR CN gain was observed in 27 pts (25.7%) and correlated significantly with high SUVmax (p 

Conclusions

Choline uptake was significantly related to plasma AR CN gain as well as elevated NLR, CgA, and LDH values. This analysis identified independent predictors of survival in mCRPC and more accurate prognostic distinct groups using molecular, laboratory and imaging features. The potential integration of these non-invasive biomarkers could be as a tool for a better treatment selection of CRPC. A larger prospective evaluation is warranted.

Clinical trial identification

None

Legal entity responsible for the study

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS.

Funding

None

Disclosure

V. Conteduca: Speaker honoraria or travel support: Astellas, Janssen-Cilag and Sanofi-Aventis. G. Attard: Honoraria, consulting fees, or travel support: Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, ESSA Pharmaceuticals, and Sanofi-Aventis; grant support: Janssen, AstraZeneca, Arno. U. De Giorgi: Speaker honoraria or travel support: Astellas, Janssen-Cilag and Sanofi- Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.